Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБНУ Научный центр психического здоровья. 115522, Россия, Москва, Каширское ш., д. 34; 2ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
Список исп. литературыСкрыть список 1. Depression: a Global Public Health Concern. World Health Organization 2012. 2. Lépine JP, Briley M. The Increasing Burden of Depression. J Neuropsychiatr Disease Treat 2011; 7: 3–7. 3. Reddy MS. Depression: The Disorder and the Burden. Indian J Psychol Med 2010; 32: 1–2. 4. Pakriev S, Kovalev J, Mozhaev M. Prevalence of Depression in a General Hospital in Izhevsk, Russia. Nordic J Psychiatry 2009; 63: 469–74. 5. Bobak M, Pikhart H, Pajak A et al. Depressive Symptoms in Urban Population Samples in Russia, Poland and the Czech Republic. Br J Psychiatry 2006; 188: 359–65. 6. Nicholson A, Pikhart H, Pajak A et al. Socio-economic Status over the Life-Course and Depressive Symptoms in Men and Women in Eastern Europe. J Affect Disord 2008; 105: 125–36. 7. Patel D. Depression is the Most Common Mental Disorder in Community Settings, and Is a Major Cause of Disability. Occupat Medicine (London) 2008; 58: 453. 8. Гурович И.Я., Шмуклер А.Б., Сторожакова Я.А. и др. Частота выявления депрессивных нарушений и их терапия при шизофрении и расстройствах шизофренического спектра в клинической практике в России. Журн. неврологии и психиатрии им. С.С.Корсакова. 2013; 113 (11–2): 28–33. / Gurovich I.Ia., Shmukler A.B., Storozhakova Ia.A. i dr. Chastota vyiavleniia depressivnykh narushenii i ikh terapiia pri shizofrenii i rasstroistvakh shizofrenicheskogo spektra v klinicheskoi praktike v Rossii. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2013; 113 (11–2): 28–33. [in Russian] 9. Смулевич А.Б., Дробижев М.А., Иванов С.В. Шизофрения и расстройства шизофренического спектра в соматическом стационаре. Журн. неврологии и психиатрии им. С.С.Корсакова. 2002; 7: 9–13. / Smulevich A.B., Drobizhev M.A., Ivanov S.V. Shizofreniia i rasstroistva shizofrenicheskogo spektra v somaticheskom statsionare. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2002; 7: 9–13. [in Russian] 10. Смулевич А.Б. Депрессии и шизофрения. Журн. неврологии и психиатрии им. С.С.Корсакова. 2003; 103: 4–13. / Smulevich A.B. Depressii i shizofreniia. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2003; 103: 4–13. [in Russian] 11. Козырев В.Н., Смулевич А.Б., Дробижев М.Ю. и др. Психотропные средства, применяемые в психиатрическом стационаре (фармакоэпидемиологические аспекты). Журн. неврологии и психиатрии им. С.С.Корсакова. 2003; 103: 25–32. / Kozyrev V.N., Smulevich A.B., Drobizhev M.Iu. i dr. Psikhotropnye sredstva, primeniaemye v psikhiatricheskom statsionare (farmakoepidemiologicheskie aspekty). Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2003; 103: 25–32. [in Russian] 12. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Eds. G.Gartlehner, R.A.Hansen, P.Thieda et al. Agency for Healthcare Research and Quality, Rockville 2007. 13. Von Wolff A, Hölzel LP, Westphal A et al. Selective Serotonin Reuptake Inhibitors and Tricyclic Antidepressants in the Acute Treatment of Chronic Depression and Dysthymia: A Systematic Review and Meta-Analysis. J Affect Disord 2013; 144: 7–15. 14. National Institute for Health and Clinical Excellence Depression: The Treatment and Management of Depression in Adults (Update). National Clinical Practice Guideline [CG90] 2009. 15. Hachisu M, Ichimaru Y. Pharmacological and Clinical Aspects of Fluvoxamine (Depromel): The First Selective Serotonin Reuptake Inhibitor Approved for Clinical Use Employed in Japan. Folia Pharmac Japonica 2000; 115: 271–9. 16. Hrdina PD. Pharmacology of Serotonin Uptake Inhibitors: Focus on Fluvoxamine. J Psychiat Neurosci 1991; 16: 10–8. 17. Fabre L, Birkhimer LJ, Zaborny BA et al. Fluvoxamine versus Imipramine and Placebo: A Double-Blind Comparison in Depressed Patients. Int Clin Psychopharmacol 1996; 11: 119–27. 18. Kasper S, Möller HJ, Montgomery SA, Zondag E. Antidepressant Efficacy in Relation to Item Analysis and Severity of Depression: A Placebo-Controlled Trial of Fluvoxamine versus Imipramine. Int Clin Psychopharmacol 1995; 9: 3–12. 19. Dalery J, Honig A. Fluvoxamine versus Fluoxetine in Major Depressive Episode: A Double-Blind Randomized Comparison. Human Psychopharmacol 2003; 18: 379–84. 20. Westenberg HG, Sandner C. Tolerability and Safety of Fluvoxamine and Other Antidepressants. Int J Clin Practice 2006; 60: 482–91. 21. Пантелеева Г.П., Абрамова Л.И., Коренев А.Н. Ингибиторы обратного захвата серотонина в лечении разных типов эндогенных депрессий. Журн. неврологии и психиатрии им. С.С.Корсакова. 2000; 100: 36–41. / Panteleeva G.P., Abramova L.I., Korenev A.N. Ingibitory obratnogo zakhvata serotonina v lechenii raznykh tipov endogennykh depressii. Zhurn. Nevrologii i psikhiatrii im. S.S.Korsakova. 2000; 100: 36–41. [in Russian] 22. Шейфер М.С., Цыбина М.И., Давыденко М.В. Флувоксамин (феварин) в терапии депрессии. Журн. неврологии и психиатрии им. С.С.Корсакова. 2000; 100: 64–7. / Sheifer M.S., Tsybina M.I., Davydenko M.V. Fluvoksamin (fevarin) v terapii depressii. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2000; 100: 64–7. [in Russian] 23. Незнамов Г.Г., Сюняков С.А., Телешова Е.С. и др. Терапевтическое действие и эффективность феварина (флувоксамина) у больных с непсихотическими тревожными апатоадинамическими депрессиями. Журн. неврологии и психиатрии им. С.С.Корсакова. 2001; 101: 19–24. / Neznamov G.G., Siuniakov S.A., Teleshova E.S. i dr. Terapevticheskoe deistvie i effektivnost' fevarina (fluvoksamina) u bol'nykh s nepsikhoticheskimi trevozhnymi apatoadinamicheskimi depressiiami. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2001; 101: 19–24. [in Russian] 24. Averina M, Nilssen O, Brenn T et al. Social and Lifestyle Determinants of Depression, Anxiety, Sleeping Disorders and Self-Evaluated Quality of Life in Russia – A Population-Based Study in Arkhangelsk. Soc Psychiatry Psychiatr Epidemiol 2005; 40: 511–8. 25. Gafarov VV, Panov DO, Gromova EA et al. The Influence of Depression on Risk Development of Acute Cardiovascular Diseases in the Female Population Aged 25–64 in Russia. Int J Circumpolar Health 2013. 26. Sonawalla SB, Spillmann MK, Kolsky AR et al. Efficacy of Fluvoxamine in the Treatment of Major Depression with Comorbid Anxiety Disorders. J Clin Psychiatry 1999; 60: 580–3. 27. Furuse T, Hashimoto K. Fluvoxamine Monotherapy for Psychotic Depression: The Potential Role of Sigma-1 Receptors. Ann General Psychiatry 2009; 8: 26. 28. Kishimoto A, Todani A, Miura J et al. The Opposite Effects of Fluvoxamine and Sertraline in the Treatment of Psychotic Major Depression: A Case Report. Ann General Psychiatry 2010; 9: 23. 29. Zohar J, Keegstra H, Barrelet L. Fluvoxamine as Effective as Clomipramine against Symptoms of Severe Depression: Results from a Multicentre, Double-Blind Study. Hum Psychopharmacol 2003; 18: 113–9. 30. Katoh Y, Uchida S, Kawai M et al. Onset of Clinical Effects and Plasma Concentration of Fluvoxamine in Japanese Patients. Biol & Pharmaceut Bull 2010; 33: 1999–2002. 31. Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-Life Impairment in Depressive and Anxiety Disorders. Am J Psychiatry 2005; 162: 1171–8. 32. Stein M, Fyer A, Davidson J et al. Fluvoxamine Treatment of Social Phobia (Social Anxiety Disorder): A Double-Blind, Placebo-Controlled Study. Am J Psychiatry 1999; 156: 756–60. 33. Wilson SJ, Bell C, Coupland NJ, Nutt DJ. Sleep Changes During Long-Term Treatment of Depression with Fluvoxamine – A Home-Based Study. Psychopharmacology 2000; 149: 360–5. 34. Irons J. Fluvoxamine in the Treatment of Anxiety Disorders. Neuropsych Dis Treat 2005; 1: 289–99. 35. Horii A, Uno A, Kitahara T et al. Effects of Fluvoxamine on Anxiety, Depression, and Subjective Handicaps of Chronic Dizziness Patients with or Without Neuro-Otologic Diseases. J Vestibul Res 2007; 17: 1–8. 36. Omori IM, Watanabe N, Nakagawa A et al. Fluvoxamine versus Other Anti-Depressive Agents for Depression. Cochrane Database Syst Rev 2010; 17 (3); Article ID: CD006114.